Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ARIAD Pharmaceuticals, Inc.
ARIAD Announces Favorable Ruling Permitting Immediate Appeal of District Court Findings on NF-kappaB Patent in Amgen Litigation
October 25th, 2008
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that the U.S. District Court for the District of Delaware granted ARIAD's motion to permit an immediate appeal of the Court's summary judgment ruling of non-infringement by Amgen's drug, Enbrel(R) (etanercept), of seven claims of U.S. Patent No. 6,410,516 (the '516 patent). The Court also cancelled the trial scheduled for November 2008 and administratively closed the case at this time. In its summary judgment ruling, the Court found that the administration of Enbrel falls outside the scope of the asserted claims based on the Court's interpretation of these claims to exclude extracellular methods of reducing...
Source: Law & Health Weekly (2008-10-25)
|
